Dynavax Technologies Co. (NASDAQ:DVAX) saw some unusual options trading on Monday. Traders acquired 1,166 put options on the stock. This is an increase of 672% compared to the typical volume of 151 put options.
In related news, VP David Louis Johnson sold 20,765 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total value of $187,507.95. Following the completion of the transaction, the vice president now directly owns 52,786 shares of the company’s stock, valued at $476,657.58. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Robert Coffman sold 63,202 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total value of $570,714.06. Following the completion of the transaction, the senior vice president now directly owns 86,268 shares of the company’s stock, valued at $779,000.04. The disclosure for this sale can be found here. Insiders sold 119,411 shares of company stock valued at $1,075,091 over the last three months. 3.47% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Dynavax Technologies by 9.6% in the fourth quarter. Geode Capital Management LLC now owns 650,953 shares of the biopharmaceutical company’s stock worth $5,956,000 after purchasing an additional 57,082 shares during the period. FMR LLC grew its position in shares of Dynavax Technologies by 39.1% during the 4th quarter. FMR LLC now owns 2,055,785 shares of the biopharmaceutical company’s stock worth $18,810,000 after buying an additional 577,868 shares during the period. Millennium Management LLC grew its position in shares of Dynavax Technologies by 513.7% during the 4th quarter. Millennium Management LLC now owns 614,930 shares of the biopharmaceutical company’s stock worth $5,627,000 after buying an additional 514,736 shares during the period. Wall Street Access Asset Management LLC grew its position in shares of Dynavax Technologies by 7.0% during the 4th quarter. Wall Street Access Asset Management LLC now owns 15,300 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 1,000 shares during the period. Finally, Macquarie Group Ltd. acquired a new position in shares of Dynavax Technologies during the 4th quarter worth about $4,575,000. 88.07% of the stock is owned by institutional investors.
Several research analysts recently commented on the company. Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, November 28th. BidaskClub raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, January 16th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price (down from $32.00) on shares of Dynavax Technologies in a research report on Tuesday, February 26th. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $27.00.
Shares of NASDAQ DVAX opened at $7.78 on Tuesday. Dynavax Technologies has a 52-week low of $7.63 and a 52-week high of $22.80. The company has a quick ratio of 4.08, a current ratio of 4.58 and a debt-to-equity ratio of 1.60.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04). The company had revenue of $3.90 million for the quarter, compared to the consensus estimate of $3.43 million. Dynavax Technologies had a negative net margin of 1,938.27% and a negative return on equity of 139.00%. The firm’s revenue was up 18471.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.45) earnings per share. Research analysts forecast that Dynavax Technologies will post -2.1 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Traders Purchase Large Volume of Put Options on Dynavax Technologies (DVAX)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2019/03/19/traders-purchase-large-volume-of-put-options-on-dynavax-technologies-dvax.html.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Further Reading: Growth Stocks
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.